226 related articles for article (PubMed ID: 15309513)
1. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
2. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
3. Chemopreventive effects of dietary folate on intestinal polyps in Apc+/-Msh2-/- mice.
Song J; Sohn KJ; Medline A; Ash C; Gallinger S; Kim YI
Cancer Res; 2000 Jun; 60(12):3191-9. PubMed ID: 10866310
[TBL] [Abstract][Full Text] [Related]
4. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
6. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
7. Large bowel adenomas: markers of risk and endpoints.
Baron JA
J Cell Biochem Suppl; 1996; 25():142-8. PubMed ID: 9027611
[TBL] [Abstract][Full Text] [Related]
8. Aberrant crypt foci: detection, gene abnormalities, and clinical usefulness.
Takayama T; Miyanishi K; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Kogawa T; Abe T; Niitsu Y
Clin Gastroenterol Hepatol; 2005 Jul; 3(7 Suppl 1):S42-5. PubMed ID: 16012995
[TBL] [Abstract][Full Text] [Related]
9. Aberrant crypt focus size predicts distal polyp histopathology.
Kim J; Ng J; Arozulllah A; Ewing R; Llor X; Carroll RE; Benya RV
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1155-62. PubMed ID: 18483337
[TBL] [Abstract][Full Text] [Related]
10. [Aberrant crypt foci as biomarkers in chemoprevention for colorectal cancer].
Katsuki S; Oui M; Takayama T; Takahashi Y; Shuichi N; Niitsu Y
Nihon Geka Gakkai Zasshi; 1998 Jun; 99(6):379-84. PubMed ID: 9695076
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of colorectal cancer.
Gwyn K; Sinicrope FA
Am J Gastroenterol; 2002 Jan; 97(1):13-21. PubMed ID: 11808936
[TBL] [Abstract][Full Text] [Related]
12. Aberrant crypt foci of the colon as precursors of adenoma and cancer.
Takayama T; Katsuki S; Takahashi Y; Ohi M; Nojiri S; Sakamaki S; Kato J; Kogawa K; Miyake H; Niitsu Y
N Engl J Med; 1998 Oct; 339(18):1277-84. PubMed ID: 9791143
[TBL] [Abstract][Full Text] [Related]
13. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis.
Mori H; Yamada Y; Kuno T; Hirose Y
Mutat Res; 2004 May; 566(3):191-208. PubMed ID: 15082237
[TBL] [Abstract][Full Text] [Related]
14. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
Takayama T; Nagashima H; Maeda M; Nojiri S; Hirayama M; Nakano Y; Takahashi Y; Sato Y; Sekikawa H; Mori M; Sonoda T; Kimura T; Kato J; Niitsu Y
Clin Cancer Res; 2011 Jun; 17(11):3803-11. PubMed ID: 21385928
[TBL] [Abstract][Full Text] [Related]
15. Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis.
Kukitsu T; Takayama T; Miyanishi K; Nobuoka A; Katsuki S; Sato Y; Takimoto R; Matsunaga T; Kato J; Sonoda T; Sakamaki S; Niitsu Y
Clin Cancer Res; 2008 Jan; 14(1):48-54. PubMed ID: 18172251
[TBL] [Abstract][Full Text] [Related]
16. Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Peek RM
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S50-6. PubMed ID: 15309515
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of large bowel carcinogenesis; the role of control of cell proliferation and significance of beta-catenin-accumulated crypts as a new biomarker.
Mori H; Yamada Y; Hirose Y; Kuno T; Katayama M; Sakata K; Yoshida K; Sugie S; Hara A; Yoshimi N
Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S71-5. PubMed ID: 12570338
[TBL] [Abstract][Full Text] [Related]
18. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans.
Rudolph RE; Dominitz JA; Lampe JW; Levy L; Qu P; Li SS; Lampe PD; Bronner MP; Potter JD
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):605-8. PubMed ID: 15767337
[TBL] [Abstract][Full Text] [Related]
20. Classification of aberrant crypt foci and microadenomas in human colon.
Roncucci L; Medline A; Bruce WR
Cancer Epidemiol Biomarkers Prev; 1991; 1(1):57-60. PubMed ID: 1845171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
